Org 25543 hydrochloride

Modify Date: 2023-01-29 19:21:48

Org 25543 hydrochloride structure	Common Name	Org 25543 hydrochloride
	CAS Number	495076-64-7	Molecular Weight	448.98
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₄H₃₃ClN₂O₄	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Org 25543 hydrochloride

Org 25543 hydrochloride is a selective and irreversible GlyT2 inhibitor (IC50: 16 nM). Org 25543 hydrochloride has analgesia effect. Org 25543 hydrochloride ameliorates mechanical allodynia after partial sciatic nerve ligation injury in mice[1][2][3].

Name	4-(Benzyloxy)-N-{[1-(dimethylamino)cyclopentyl]methyl}-3,5-dimethoxybenzamide hydrochloride (1:1)
Synonym	More Synonyms

Description	Org 25543 hydrochloride is a selective and irreversible GlyT2 inhibitor (IC50: 16 nM). Org 25543 hydrochloride has analgesia effect. Org 25543 hydrochloride ameliorates mechanical allodynia after partial sciatic nerve ligation injury in mice[1][2][3].
Related Catalog	Signaling Pathways >> Membrane Transporter/Ion Channel >> GlyT Research Areas >> Neurological Disease Signaling Pathways >> Neuronal Signaling >> GlyT
References	[1]. Caulfield WL, et al. The first potent and selective inhibitors of the glycine transporter type 2. J Med Chem. 2001 Aug 16;44(17):2679-82. [2]. Morita K, et al. Spinal antiallodynia action of glycine transporter inhibitors in neuropathic pain models in mice. J Pharmacol Exp Ther. 2008 Aug;326(2):633-45. [3]. Mohammadzadeh A, et al. Pharmacological Evidence on Augmented Antiallodynia Following Systemic Co-Treatment with GlyT-1 and GlyT-2 Inhibitors in Rat Neuropathic Pain Model. Int J Mol Sci. 2021 Mar 1;22(5):2479.

Description

Related Catalog

Signaling Pathways >> Membrane Transporter/Ion Channel >> GlyT

Research Areas >> Neurological Disease

Signaling Pathways >> Neuronal Signaling >> GlyT

References

[1]. Caulfield WL, et al. The first potent and selective inhibitors of the glycine transporter type 2. J Med Chem. 2001 Aug 16;44(17):2679-82.

[2]. Morita K, et al. Spinal antiallodynia action of glycine transporter inhibitors in neuropathic pain models in mice. J Pharmacol Exp Ther. 2008 Aug;326(2):633-45.

[3]. Mohammadzadeh A, et al. Pharmacological Evidence on Augmented Antiallodynia Following Systemic Co-Treatment with GlyT-1 and GlyT-2 Inhibitors in Rat Neuropathic Pain Model. Int J Mol Sci. 2021 Mar 1;22(5):2479.